Patent Issued for Arsinothricin as a multi-stage antimalarial (USPTO 11877996).
In: Zika & Mosquito Week, 2024-02-13, S. 3705-3705
serialPeriodical
Zugriff:
Florida International University Board of Trustees has been issued a patent for arsinothricin as a multi-stage antimalarial. Malaria is a severe vector-borne disease that causes millions of cases and deaths worldwide. The patent describes the use of arsinothricin as an antimalarial agent that inhibits the essential enzyme glutamine synthetase of malaria pathogens with less toxicity to humans. The invention provides methods for treating and preventing malaria infection and transmission, and the patent claims cover the use of arsinothricin or its salt for these purposes. [Extracted from the article]
Copyright of Zika & Mosquito Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Arsinothricin as a multi-stage antimalarial (USPTO 11877996).
|
---|---|
Zeitschrift: | Zika & Mosquito Week, 2024-02-13, S. 3705-3705 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
Schlagwort: |
|
Sonstiges: |
|